Recent advances in the diagnosis and management of Gaucher disease

References

• Nalysnyk L, Rotella P, Simeone JC, et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22(2):65–73.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Tsuji S, Stubblefield BK, et al. Gaucher patients with oculomotor abnormalities do not have a unique genotype. Clin Genet. 1992;41(1):1–5.
   PubMed Web of Science ®Google Scholar
• Elstein D, Altarescu G, Abrahamov A, et al. Children with type 1 Gaucher disease: changing profiles in the 21st century. Blood Cells Mol Dis. 2016;68:93–96.
   Web of Science ®Google Scholar
• Burton BK, Charrow J, Hoganson GE, et al. Newborn screening for lysosomal storage disorders in illinois: the initial 15-month experience. J Pediatr. 2017;190:130–135.
   Web of Science ®Google Scholar
• Hopkins PV, Campbell C, Klug T, et al. Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr. 2015;166(1):172–177.
   PubMed Web of Science ®Google Scholar
• Andrade-Campos M, Alfonso P, Irun P, et al. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish registry of Gaucher disease. Orphanet J Rare Dis. 2017;12(1):84.
   PubMedGoogle Scholar
• Yang AC, Bier L, Overbey JR, et al. Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening. Genet Med off J Am Coll Med Genet. 2017;19(6):652–658.
   Google Scholar
• Mignot C, Gelot A, Bessieres B, et al. Perinatal-lethal Gaucher disease. Am J Med Genet A. 2003;120A(3):338–344.
   PubMed Web of Science ®Google Scholar
• Bruwer Z, Al Riyami N, Al Dughaishi T, et al. Inborn errors of metabolism in a cohort of pregnancies with non-immune hydrops fetalis: a single center experience. J Perinat Med. 2017. doi:10.1515/jpm-2017-0124
   PubMedGoogle Scholar
• Bellini C, Donarini G, Paladini D, et al. Etiology of non-immune hydrops fetalis: an update. Am J Med Genet A. 2015;167A(5):1082–1088.
   PubMedGoogle Scholar
• Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr. 1999;46:409–440.
   PubMedGoogle Scholar
• Staretz-Chacham O, Lang TC, LaMarca ME, et al. Lysosomal storage disorders in the newborn. Pediatrics. 2009;123(4):1191–1207.
   PubMed Web of Science ®Google Scholar
• Carr PC, Casamiquela KM, Jacks SK. Gaucher disease Type 2 presenting with collodion membrane and blueberry muffin lesions. Pediatr Dermatol. 2016;33(1):e20–22.
   PubMed Web of Science ®Google Scholar
• Roshan Lal T, Sidransky E. The spectrum of neurological manifestations associated with Gaucher disease. Diseases. 2017;5:1.
   Google Scholar
• Gupta N, Oppenheim IM, Kauvar EF, et al. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011;46(1):75–84.
   PubMed Web of Science ®Google Scholar
• Weiss K, Gonzalez A, Lopez G, et al. The clinical management of type 2 Gaucher disease. Mol Genet Metab. 2015;114(2):110–122.
   PubMedGoogle Scholar
• Wolf P, Alcalay RN, Liong C, et al. Tandem mass spectrometry assay of beta-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay. Mol Genet Metab. 2018;123(2):135–139.
   PubMed Web of Science ®Google Scholar
• Mehta A, Belmatoug N, Bembi B, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122(3):122–129.
   Web of Science ®Google Scholar
• Di Rocco M, Andria G, Deodato F, et al. Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm. Pediatr Blood Cancer. 2014;61(11):1905–1909.
   PubMed Web of Science ®Google Scholar
• Kaplan P, Andersson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006;160(6):603–608.
   PubMed Web of Science ®Google Scholar
• Benko W, Ries M, Wiggs EA, et al. The saccadic and neurological deficits in type 3 Gaucher disease. PLoS One. 2011;6(7):e22410.
   PubMed Web of Science ®Google Scholar
• Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr. 2004;163(2):67–75.
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol. 2015;90(Suppl 1):S12–18.
   PubMedGoogle Scholar
• Dar L, Tiomkin M, Elstein D, et al. Bone mineral density and lean muscle mass characteristics in children with Gaucher disease treated with enzyme replacement therapy or untreated. Blood Cells Mol Dis. 2018;68:135–138.
   PubMed Web of Science ®Google Scholar
• Mendelsohn E, Meir A, Abrahamov A, et al. Growth and final height of children with Gaucher disease: a 15-year follow-up at an Israeli Gaucher center. Blood Cells Mol Dis. 2018;68:97–99.
   PubMedGoogle Scholar
• Mistry PK, Weinreb NJ, Kaplan P, et al. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis. 2011;46(1):66–72.
   PubMed Web of Science ®Google Scholar
• Baldini M, Casirati G, Ulivieri FM, et al. Skeletal involvement in type 1 Gaucher disease: not just bone mineral density. Blood Cells Mol Dis. 2017;68:148–152.
   PubMedGoogle Scholar
• Drelichman G, Fernandez Escobar N, Basack N, et al. Skeletal involvement in Gaucher disease: an observational multicenter study of prognostic factors in the Argentine Gaucher disease patients. Am J Hematol. 2016;91(10):E448–453.
   PubMed Web of Science ®Google Scholar
• Guimarães J, Amaral O, Sá Miranda MC. Adult-onset neuronopathic form of Gaucher’s disease: a case report. Parkinsonism Relat Disord. 2003;9(5):261–264.
   PubMed Web of Science ®Google Scholar
• Park JK, Orvisky E, Tayebi N, et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res. 2003;53(3):387–395.
   PubMed Web of Science ®Google Scholar
• Altarescu G, Hill S, Wiggs E, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr. 2001;138(4):539–547.
   PubMed Web of Science ®Google Scholar
• Garvey MA, Toro C, Goldstein S, et al. Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease. Neurology. 2001;56:391–394.
   PubMed Web of Science ®Google Scholar
• Tantawy AA, Sherif EM, Adly AA, et al. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience. J Inherit Metab Dis. 2013;36(6):1025–1037.
   PubMed Web of Science ®Google Scholar
• Goker-Alpan O, Wiggs EA, Eblan MJ, et al. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Pediatr. 2008;153(1):89–94.
   PubMed Web of Science ®Google Scholar
• Campbell PE, Harris CM, Vellodi A. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology. 2004;63:385–387.
   PubMed Web of Science ®Google Scholar
• Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis. 2009;43(3):264–288.
   PubMed Web of Science ®Google Scholar
• Lau H, Belmatoug N, Deegan P, et al. Reported outcomes of 453 pregnancies in patients with Gaucher disease: an analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 2018;68:226–231.
   PubMed Web of Science ®Google Scholar
• Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156:3–8.
   PubMed Web of Science ®Google Scholar
• Rosenbaum H. Management of women with Gaucher disease in the reproductive age. Thromb Res. 2015;135(Suppl 1):S49–51.
   PubMedGoogle Scholar
• Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab. 2002;77(1–2):91–98.
   PubMed Web of Science ®Google Scholar
• de Boer GM, van Dussen L, Van Den Toorn LM, et al. Lung transplantation in Gaucher disease: a learning lesson in trying to avoid both scylla and charybdis. Chest. 2016;149(1):e1–5.
   PubMed Web of Science ®Google Scholar
• Rosenbaum H, Sidransky E. Cholelithiasis in patients with Gaucher disease. Blood Cells Mol Dis. 2002;28(1):21–27.
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Lee RE. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher disease who were never treated with enzyme replacement therapy. Crit Rev Oncog. 2013;18(3):177–195.
   PubMedGoogle Scholar
• Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher registry. Blood. 2005;105:4569–4572.
   PubMed Web of Science ®Google Scholar
• de Fost M, vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis. 2006;36(1):53–58.
   PubMed Web of Science ®Google Scholar
• Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84(4):208–214.
   PubMed Web of Science ®Google Scholar
• Nair S, Branagan AR, Liu J, et al. Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med. 2016;374(6):555–561.
   PubMed Web of Science ®Google Scholar
• Arends M, van Dussen L, Biegstraaten M, et al. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature. Br J Haematol. 2013;161(6):832–842.
   PubMed Web of Science ®Google Scholar
• Zimran A, Liphshitz I, Barchana M, et al. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis. 2005;34(3):197–200.
   PubMed Web of Science ®Google Scholar
• Madeo A, Garaventa A, Sementa AR, et al. The unusual association between neuroblastoma and Gaucher disease: case report and review of the literature. Blood Cells Mol Dis. 2018;68(Supplement C):106–108.
   PubMedGoogle Scholar
• Kojiro M, Kage M, Abe H, et al. Association of dysgerminoma and gaucher’s disease. Cancer. 1983;51(4):712–715.
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604.
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Biol. 2008;9:139.
   PubMed Web of Science ®Google Scholar
• Pavlova EV, Archer J, Wang S, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol. 2015;235(1):113–124.
   PubMed Web of Science ®Google Scholar
• Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79:104–109.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361:1651–1661.
   PubMed Web of Science ®Google Scholar
• Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41:937–940.
   PubMed Web of Science ®Google Scholar
• Lopez G, Kim J, Wiggs E, et al. Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurol Genet. 2016;2(2):e57.
   PubMedGoogle Scholar
• Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease. Brain. 2014;137(3):834–848.
   PubMedGoogle Scholar
• Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37–52.
   PubMed Web of Science ®Google Scholar
• Cullen V, Sardi SP, Ng J, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol. 2011;69(6):940–953.
   PubMed Web of Science ®Google Scholar
• Gan-Or Z, Amshalom I, Kilarski LL, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology. 2015;84:880–887.
   PubMed Web of Science ®Google Scholar
• Goker-Alpan O, Hruska KS, Orvisky E, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet. 2005;42(6):e37.
   PubMed Web of Science ®Google Scholar
• Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002;76(4):262–270.
   PubMed Web of Science ®Google Scholar
• Mistry PK, Lopez G, Schiffmann R, et al. Gaucher disease: progress and ongoing challenges. Mol Genet Metab. 2017;120:8–21.
   PubMedGoogle Scholar
• Zhang CK, Stein PB, Liu J, et al. Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. Am J Hematol. 2012;87(4):377–383.
   PubMed Web of Science ®Google Scholar
• Klein Andrés D, Ferreira N-S, Ben-Dor S, et al. Identification of modifier genes in a mouse model of Gaucher disease. Cell Rep. 2016;16(10):2546–2553.
   PubMed Web of Science ®Google Scholar
• Jian J, Tian Q-Y, Hettinghouse A, et al. Progranulin recruits HSP70 to β-glucocerebrosidase and is therapeutic against Gaucher disease. EBioMedicine. 2016;13:212–224.
   PubMed Web of Science ®Google Scholar
• George R, McMahon J, Lytle B, et al. Severe valvular and aortic arch calcification in a patient with Gaucher’s disease homozygous for the D409H mutation. Clin Genet. 2001;59(5):360–363.
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet (London, England). 2008;372(9645):1263–1271.
   PubMed Web of Science ®Google Scholar
• Mistry PK, Belmatoug N, vom Dahl S, et al. Understanding the natural history of Gaucher disease. Am J Hematol. 2015;90(Suppl 1):S6–11.
   PubMedGoogle Scholar
• Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: a review. Br J Radiol. 2002;75(Suppl 1):A2–12.
   PubMedGoogle Scholar
• Mikosch P. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone. Best Pract Res Clin Rheumatol. 2011;25(5):665–681.
   PubMedGoogle Scholar
• Goker-Alpan O, Schiffmann R, Park JK, et al. Phenotypic continuum in neuronopathic gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr. 2003;143(2):273–276.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the international collaborative Gaucher group Gaucher registry. Mol Genet Metab. 2017;120(1):47–56.
   PubMed Web of Science ®Google Scholar
• Chan A, Holleran W, Ferguson T, et al. Skin ultrastructural findings in type 2 Gaucher disease: diagnostic implications. Mol Genet Metab. 2011;104(4):631–636.
   PubMed Web of Science ®Google Scholar
• Cilia R, Tunesi S, Marotta G, et al. Survival and dementia in GBA-associated Parkinson’s disease: the mutation matters. Ann Neurol. 2016;80:662–673.
   PubMed Web of Science ®Google Scholar
• Davis MY, Johnson CO, Leverenz JB, et al. Association of gba mutations and the e326k polymorphism with motor and cognitive progression in parkinson disease. JAMA Neurol. 2016;73(10):1217–1224.
   PubMed Web of Science ®Google Scholar
• Mallett V, Ross JP, Alcalay RN, et al. GBA p.T369M substitution in Parkinson disease: polymorphism or association? A meta-analysis. Neurol Genet. 2016;2(5):e104.
   PubMedGoogle Scholar
• Gary SE, McMahon B, Lopez G, et al. Glucocerebrosidase mutations and parkinsonism: how much does the mutation matter? J Xiangya Med. 2018;3:1.
   Google Scholar
• Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70:727.
   PubMed Web of Science ®Google Scholar
• Shiner T, Mirelman A, Gana Weisz M, et al. High frequency of gba gene mutations in dementia with lewy bodies among ashkenazi jews. JAMA Neurol. 2016;73:1448–1453.
   PubMed Web of Science ®Google Scholar
• Tsuang D, Leverenz JB, Lopez OL, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 2012;79:1944–1950.
   PubMed Web of Science ®Google Scholar
• Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122:359–369.
   PubMed Web of Science ®Google Scholar
• Hollak CE, van Weely S, Van Oers MH, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Investig. 1994;93:1288–1292.
   PubMed Web of Science ®Google Scholar
• Dekker N, van Dussen L, Hollak CEM, et al. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood. 2011;118:e118–e127.
   PubMed Web of Science ®Google Scholar
• Rolfs A, Giese A-K, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish. Caucasian Cohort Gaucher Disease Patients PLoS ONE. 2013;8:e79732.
   Google Scholar
• Watad S, Abu-Saleh N, Yousif A, et al. The role of high density lipoprotein in type 1 Gaucher disease. Blood Cells Mol Dis. 2018;68:43–46.
   PubMedGoogle Scholar
• Murugesan V, Liu J, Yang R, et al. Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells Mol Dis. 2018;68:47–53.
   PubMed Web of Science ®Google Scholar
• Lorenz F, Pawłowicz E, Klimkowska M, et al. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1. Blood Cells Mol Dis. 2018;68:35–42.
   PubMed Web of Science ®Google Scholar
• Jian J, Hettinghouse A, C-J L. Progranulin acts as a shared chaperone and regulates multiple lysosomal enzymes. Genes & Dis. 2017;4(3):125–126.
   PubMed Web of Science ®Google Scholar
• Boot RG, Verhoek M, De Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103:33–39.
   PubMed Web of Science ®Google Scholar
• Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35:259–267.
   PubMed Web of Science ®Google Scholar
• van Dussen L, Akkerman EM, Hollak CEM, et al. Evaluation of an imaging biomarker, dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned. J Inherit Metab Dis. 2014;37:1003–1011.
   PubMed Web of Science ®Google Scholar
• Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to dixon quantitative chemical shift MR imaging—initial experience. Radiology. 2003;229:554–561.
   PubMed Web of Science ®Google Scholar
• Igci N, Sharafi P, Demiralp DO, et al. Application of Fourier transform infrared spectroscopy to biomolecular profiling of cultured fibroblast cells from Gaucher disease patients: A preliminary investigation. Advances Clinical Experimental Medicine: Official Organ Wroclaw Medical University. 2017;26:1053–1061.
   PubMed Web of Science ®Google Scholar
• Webb M, Zimran A, Dinur T, et al. Are transient and shear wave elastography useful tools in Gaucher disease? Blood Cells Mol Dis. 2018;68:143–147.
   PubMedGoogle Scholar
• Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018;68(Supplement C):203–208.
   PubMedGoogle Scholar
• Brady RO, Kanfer JN, Bradley RM, et al. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J Clin Investig. 1966;45(7):1112–1115.
   PubMedGoogle Scholar
• Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency–macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324:1464–1470.
   PubMed Web of Science ®Google Scholar
• Brady RO. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res. 2006;9:237–244.
   PubMed Web of Science ®Google Scholar
• Pastores GM, Shankar SP, Petakov M, et al. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Am J Hematol. 2016;91:661–665.
   PubMed Web of Science ®Google Scholar
• Pastores GM, Rosenbloom B, Weinreb N, et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med. 2014;16:359–366.
   PubMed Web of Science ®Google Scholar
• Zimran A, Pastores GM, Tylki-Szymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013;88:172–178.
   PubMed Web of Science ®Google Scholar
• Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet In Med. 2005;7:105.
   PubMed Web of Science ®Google Scholar
• Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Time. 2004;41(4 Suppl 5):4–14.
   Google Scholar
• Beutler E, Demina A, Laubscher K, et al. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis. 1995;21:86–108.
   PubMed Web of Science ®Google Scholar
• Zimran A, Hadas-Halpern I, Zevin S, et al. Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br J Haematol. 1993;85:783–786.
   PubMed Web of Science ®Google Scholar
• Cohen IJ, Katz K, Kornreich L, et al. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis. 1998;24:296–302.
   PubMed Web of Science ®Google Scholar
• Wilson C, Spearing R, Teague L, et al. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy. Mol Genet Metab. 2007;92:131–136.
   PubMed Web of Science ®Google Scholar
• Goldblatt J, Fletcher JM, McGill J, et al. Enzyme replacement therapy “drug holiday”: results from an unexpected shortage of an orphan drug supply in Australia. Blood cells Mol Dis. 2011;46:107–110.
   PubMed Web of Science ®Google Scholar
• Andersson H, Kaplan P, Kacena K, et al. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122:1182–1190.
   PubMed Web of Science ®Google Scholar
• Cheema HA, Malik HS, Parkash A, et al. Spectrum of inherited metabolic disorders in Pakistani children presenting at a tertiary care centre. Jcpsp. 2016;26:498–502.
   Google Scholar
• Radin NS, Arora RC, Ullman MD, et al. A possible therapeutic approach to Krabbe’s globoid leukodystrophy and the status of cerebroside synthesis in the disorder. Res Commun Chem Pathol Pharmacol. 1972;3:637–644.
   PubMedGoogle Scholar
• Shayman JA. Synthesis inhibition therapy for Gaucher disease. In: Advances in Gaucher disease: basic and clinical perspectives. Future Medicine Ltd, Grabowski: London; 2013. p. 240–256.
   Google Scholar
• Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet (London, England). 2000;355:1481–1485.
   PubMed Web of Science ®Google Scholar
• Elstein D, Hollak C, Aerts JMFG, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757–766.
   PubMed Web of Science ®Google Scholar
• Giraldo P, Alfonso P, Atutxa K, et al. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica. 2009;94:1771LP–1775.
   Web of Science ®Google Scholar
• Pastores GM, Elstein D, Hrebícek M, et al. Effect of miglustat on bone disease in adults with Type 1 Gaucher disease: a pooled analysis of three multinational. Open-Label Studies. Clin Ther. 2007;29:1645–1654.
   PubMed Web of Science ®Google Scholar
• Hollak CEM, Hughes D, Van Schaik IN, et al. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18:770–777.
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Mehta A, Hollak CEM, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013;51:116–124.
   PubMed Web of Science ®Google Scholar
• Giraldo P, Andrade-Campos M, Alfonso P, et al. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: the Spanish ZAGAL project. Blood Cells Mol Dis. 2018;68(Supplement C):173–179.
   PubMedGoogle Scholar
• Peterschmitt MJ, Cox GF, Ibrahim J, et al. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration. Blood Cells Mol Dis. 2018;68:185–191.
   PubMed Web of Science ®Google Scholar
• Zimran A, Goldblatt J, Szer J. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. Blood Cells Mol Dis. 2017;68:14–16.
   PubMed Web of Science ®Google Scholar
• Dulsat C, Mealy N. Isofagomine tartrate. Drugs Fut. 2009;34:23.
   Web of Science ®Google Scholar
• Therapeutics A Amicus therapeutics announces preliminary results of phase 2 study with plicera for Gaucher disease. zu finden unter. [cited 2018 Jan17]. Available from: http://ir.amicustherapeutics.com/releasedetail.cfm.
   Google Scholar
• Maegawa GHB, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284:23502–23516.
   PubMed Web of Science ®Google Scholar
• Bendikov-Bar I, Maor G, Filocamo M, et al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis. 2013;50:141–145.
   PubMed Web of Science ®Google Scholar
• Narita A, Shirai K, Itamura S, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Trans Neurol. 2016;3:200–215.
   PubMed Web of Science ®Google Scholar
• Aflaki E, Stubblefield BK, Maniwang E, et al. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci Transl Med. 2014;6:240ra273.
   Web of Science ®Google Scholar
• Aflaki E, Borger DK, Moaven N, et al. A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism. J Neurosci off J Soc Neurosci. 2016;36:7441–7452.
   PubMed Web of Science ®Google Scholar
• Jung O, Patnaik S, Marugan J, et al. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Rev Proteomics. 2016;13:1–9.
   PubMed Web of Science ®Google Scholar